Boston Scientific strengthens ties to MValve Technologies
Marlborough-based Boston Scientific Wednesday announced it is providing a new round of financing for MValve Technologies, which operates in Herzliya, Israel and San Diego.
The companies are linked through their work on mitral regurgitation, a common type of heart valve disorder. The latest investment, the amount of which was not disclosed by the company, continues their three-year alliance toward development of a replacement valve.
Further, Boston Scientific could purchase MValve in the future, the company announced. It has provided the company with funding since 2012, and has an exclusive option to acquire it.
In mitral regurgitation, the mitral valve fails to close properly, causing a blackflow of blood from the left ventricle into the left atrium. MValve plans to use part of the new financing for a first-in-human clinical trial for the MValve docking system for transcatheter mitral valve replacement, according to Boston Scientific.
MValve’s percutaneous mitral valve replacement system works with Boston Scientific’s LOTUS valve, with the Boston Scientific product deployed inside the MValve docking system. The system, the statement said, is designed to enable the treatment of mitral regurgitation in a broad range of patients, and to improve long-term clinical outcomes.
WBJ Web Partners
Most Recent
Most Recent
0 Comments